In today’s session Clovis Oncology Inc (CLVS) recorded an unusually high (225) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious CLVS decrease. With 225 contracts traded and 3264 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: CLVS170120P00025000 closed last at: $2.5 or 5.7% down. About 1.84M shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 56.85% since March 14, 2016 and is uptrending. It has outperformed by 51.24% the S&P500.
Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on November, 3. They expect $-1.93 earnings per share, up 26.34% or $0.69 from last year’s $-2.62 per share. After $-2.07 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -6.76% EPS growth.
Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage
Out of 8 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Clovis Oncology has been the topic of 23 analyst reports since September 10, 2015 according to StockzIntelligence Inc. As per Wednesday, August 24, the company rating was maintained by Mizuho. The firm has “Hold” rating by WallachBeth Capital given on Monday, May 9. Goldman Sachs downgraded Clovis Oncology Inc (NASDAQ:CLVS) on Tuesday, November 17 to “Neutral” rating. On Friday, September 23 the stock rating was maintained by SunTrust with “Buy”. As per Wednesday, August 24, the company rating was maintained by SunTrust. The firm has “Neutral” rating given on Wednesday, April 13 by JP Morgan. The stock has “Buy” rating given by Suntrust Robinson on Friday, August 5. The company was maintained on Friday, February 26 by Stifel Nicolaus. Credit Suisse upgraded Clovis Oncology Inc (NASDAQ:CLVS) rating on Wednesday, September 21. Credit Suisse has “Outperform” rating and $41 price target. On Monday, April 4 the stock rating was reinitiated by Piper Jaffray with “Neutral”.
According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.13, from 0.87 in 2016Q1. The ratio improved, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
State Street accumulated 0% or 1.64M shares. Tower Cap Ltd Liability (Trc) holds 7,105 shares or 0.01% of its portfolio. Antipodean Ltd Liability, a New York-based fund reported 523,000 shares. Connor Clark And Lunn Investment Ltd has 0% invested in the company for 10,650 shares. Thompson Davis last reported 125 shares in the company. Blackrock Institutional Tru Co Na last reported 823,036 shares in the company. Renaissance Tech Limited Liability Corporation reported 307,200 shares or 0.01% of all its holdings. Alliancebernstein Limited Partnership last reported 46,340 shares in the company. Rice Hall James & Ltd Liability Company reported 94,594 shares or 0.07% of all its holdings. Blackrock reported 2,557 shares or 0% of all its holdings. Amer International Group has 18,297 shares for 0% of their US portfolio. Northern Trust has 0% invested in the company for 390,230 shares. Pnc Financial Services owns 1,608 shares or 0% of their US portfolio. Iguana Healthcare Mgmt Lc last reported 90,000 shares in the company. State Board Of Administration Of Florida Retirement System accumulated 22,819 shares or 0% of the stock.
Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has a market cap of $1.17 billion. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. It currently has negative earnings. Rociletinib is an oral epidermal growth factor receptor , mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
CLVS Company Profile
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
More recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Fool.com which released: “Why Clovis Oncology Inc. Rose 52.7% in September” on October 10, 2016. Also Fool.com published the news titled: “Why Clovis Oncology Shares Are Falling 14.5% Today” on October 07, 2016. Investorplace.com‘s news article titled: “Why Clovis Oncology Inc (CLVS), Philip Morris International Inc. (PM) And …” with publication date: September 22, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.